Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    CAMN107AUS28
Show Display Options
Rank Status Study
1 Recruiting CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: nilotinib
2 Not yet recruiting An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Condition: Leukemia
Interventions: Drug: MEK-162;   Drug: Nilotinib;   Behavioral: Questionnaires
3 Terminated
Has Results
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Condition: Myelogenous Leukemia
Interventions: Drug: Imatinib;   Drug: Nilotinib (AMN107)
4 Recruiting Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Conditions: Leukemia;   Leukemia,Pediatric;   Leukemia, Myleiod;   Leukemia, Mylegenous, Chronic;   Leukemia, Mylegenous, Accelerated;   BCR-ABL Positive;   Myeloproliferative Disorder;   Bone Marrow Disease;   Hematologic Diseases;   Neoplastic Processes;   Imatinib;   Dasatinib;   Enzyme Inhibitor;   Protein Kinase Inhibitor
Intervention: Drug: nilotinib

Indicates status has not been verified in more than two years